L
Lewis J. Rubin
Researcher at University of California, San Diego
Publications - 373
Citations - 60316
Lewis J. Rubin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Pulmonary hypertension & Bosentan. The author has an hindex of 101, co-authored 370 publications receiving 57044 citations. Previous affiliations of Lewis J. Rubin include University of Texas Health Science Center at San Antonio & Silver Spring Networks.
Papers
More filters
Journal ArticleDOI
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
Nazzareno Galiè,Sean Gaine,Richard N. Channick,J. Gerry Coghlan,Marius M. Hoeper,Irene M. Lang,Vallerie V. McLaughlin,Cheryl Lassen,Lewis J. Rubin,Shu-Fang Hsu Schmitz,Olivier Sitbon,Olivier Sitbon,Victor F. Tapson,Kelly Chin +13 more
TL;DR: The authors in this article showed that the oral prostacyclin receptor agonist selexipag significantly reduced the risk of disease progression (composite primary endpoint of morbidity/mortality), compared with placebo, in patients with pulmonary arterial hypertension (PAH).
Journal ArticleDOI
Medical Treatment of Pulmonary Arterial Hypertension
TL;DR: Monitoring and measuring the response to treatment in clinical trials and clinical practice are evolving from the historical dependence on functional class and 6-minute walk test to include estimates of the delay in the time to clinical worsening and the response of emerging biomarkers.
Journal ArticleDOI
Update on pulmonary arterial hypertension research: proceedings from a meeting of experts.
Vallerie V. McLaughlin,Matthew Bacchetta,David B. Badesch,Raymond L. Benza,Charles D. Burger,Kelly Chin,Robert P. Frantz,Adaani E. Frost,Anna R. Hemnes,Nick H. Kim,Erika B. Rosenzweig,Lewis J. Rubin +11 more
TL;DR: This paper reviews the published research and insight into upcoming research that was presented at this interactive meeting on PAH and suggests the best ways to monitor and manage patients are still to be found.
Journal ArticleDOI
An Insider View on the World Symposium on Pulmonary Hypertension
TL;DR: The most important recent advances in the medical management of PAH have not been related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response.
BookDOI
Pulmonary heart disease
TL;DR: The objective of the study was to establish a baseline for the evaluation of the relationship between the electrocardiogram and pulmonary function and exercise testing and the results confirmed that the former is more accurate than the latter.